Roy Fleischmann Selected Research

tofacitinib

1/2022	Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
1/2021	Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib.
1/2021	Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
9/2020	Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study.
1/2020	Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
1/2019	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
1/2019	Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
12/2018	A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
12/2018	Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
6/2018	Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roy Fleischmann Research Topics

Disease

111	Rheumatoid Arthritis 04/2022 - 01/2002
23	Pain (Aches) 04/2022 - 03/2002
23	Infections 01/2022 - 01/2002
13	Fatigue 04/2022 - 08/2004
13	Psoriatic Arthritis 01/2021 - 01/2002
11	Necrosis 10/2020 - 01/2002
10	Chronic Disease (Chronic Diseases) 04/2022 - 03/2008
9	Herpes Zoster 01/2022 - 06/2014
8	Neoplasms (Cancer) 01/2022 - 01/2004
7	Ankylosing Spondylitis 11/2020 - 11/2003
7	Arthritis (Polyarthritis) 09/2020 - 07/2010
7	Rheumatic Diseases (Rheumatism) 04/2013 - 01/2002
5	Osteoarthritis 04/2022 - 10/2002
5	Tuberculosis (Tuberculoses) 01/2022 - 08/2004
5	Opportunistic Infections (Opportunistic Infection) 01/2022 - 08/2004
5	Injection Site Reaction 01/2014 - 01/2002
4	Inflammation (Inflammations) 06/2019 - 01/2006
3	Psoriasis (Pustulosis Palmaris et Plantaris) 11/2020 - 01/2017
3	Disease Progression 08/2020 - 04/2007
3	Respiratory Tract Infections (Respiratory Tract Infection) 01/2018 - 11/2003
3	Gout 01/2018 - 12/2014
3	Lymphoma (Lymphomas) 03/2015 - 05/2006
2	Anemia 04/2022 - 05/2012
2	Skin Neoplasms (Skin Cancer) 01/2022 - 01/2017
2	Atopic Dermatitis (Atopic Eczema) 11/2020 - 01/2006
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 11/2020 - 05/2016
2	Urinary Tract Infections (Urinary Tract Infection) 01/2018 - 03/2012
2	Demyelinating Diseases (Demyelinating Disease) 03/2015 - 08/2004
2	Neutropenia 05/2012 - 05/2010
2	Diarrhea 05/2012 - 03/2012
2	Hypertension (High Blood Pressure) 05/2012 - 10/2002
1	Cutaneous Lupus Erythematosus 01/2022
1	Venous Thromboembolism 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	COVID-19 12/2021
1	Ulcerative Colitis 11/2020
1	Crohn Disease (Crohn's Disease) 11/2020
1	Breakthrough Infections 10/2020
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 03/2020
1	Nasopharyngitis 01/2018
1	Pulmonary Embolism 01/2018
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2018

Drug/Important Bio-Agent (IBA)

50	Methotrexate (Mexate)FDA LinkGeneric 01/2022 - 01/2002
31	tofacitinibIBA 01/2022 - 03/2012
27	Adalimumab (Humira)FDA Link 04/2022 - 01/2007
21	Antirheumatic Agents (DMARD)IBA 04/2022 - 01/2002
18	Janus Kinase InhibitorsIBA 01/2022 - 03/2012
17	Biological ProductsIBA 04/2022 - 07/2003
13	Tumor Necrosis Factor InhibitorsIBA 01/2022 - 01/2004
12	ametantrone (HAQ)IBA 04/2022 - 11/2015
10	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 01/2002
9	baricitinibIBA 01/2022 - 01/2017
8	Abatacept (Orencia)FDA Link 04/2022 - 01/2013
8	Certolizumab Pegol FDA Link 01/2018 - 01/2009
7	sarilumabIBA 11/2021 - 06/2015
6	upadacitinibIBA 02/2022 - 01/2018
6	GlucocorticoidsIBA 06/2020 - 05/2006
6	golimumab FDA Link 12/2016 - 07/2010
6	Etanercept (Enbrel)FDA Link 11/2014 - 01/2002
6	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 04/2007 - 01/2002
5	Monoclonal AntibodiesIBA 07/2021 - 01/2002
4	Adrenocorticotropic Hormone (ACTH)FDA Link 04/2022 - 06/2020
4	C-Reactive ProteinIBA 04/2022 - 01/2014
4	LipidsIBA 01/2022 - 05/2010
4	InterleukinsIBA 07/2021 - 01/2017
4	Rituximab (Mabthera)FDA Link 05/2011 - 05/2006
3	Phosphotransferases (Kinase)IBA 01/2022 - 05/2010
3	Interleukin-1 (Interleukin 1)IBA 01/2018 - 08/2004
3	Sulfasalazine (Azulfidine)FDA LinkGeneric 01/2017 - 01/2002
3	Pharmaceutical PreparationsIBA 01/2017 - 10/2002
3	Infliximab (Remicade)FDA Link 11/2014 - 01/2002
3	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 04/2007 - 01/2002
2	Anti-Citrullinated Protein AntibodiesIBA 04/2022 - 12/2019
2	Janus Kinase 1IBA 01/2022 - 01/2018
2	olokizumabIBA 07/2021 - 09/2014
2	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 10/2020 - 01/2020
2	Janus KinasesIBA 10/2020 - 09/2018
2	Biosimilar PharmaceuticalsIBA 03/2020 - 01/2018
2	Uric Acid (Urate)IBA 01/2018 - 12/2014
2	Febuxostat FDA Link 01/2018 - 12/2014
2	verinuradIBA 01/2018 - 01/2018
2	Interleukin-6 (Interleukin 6)IBA 01/2018 - 01/2017
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2017 - 01/2002
2	CreatinineIBA 05/2012 - 05/2010
2	lumiracoxib (prexige)IBA 03/2008 - 02/2006
2	Celecoxib (Celebrex)FDA Link 03/2008 - 02/2006
2	Meloxicam (Mobic)FDA LinkGeneric 10/2002 - 03/2002
2	Diclofenac (SR 38)FDA LinkGeneric 10/2002 - 03/2002
1	Hemoglobins (Hemoglobin)IBA 04/2022
1	acetyl 4-aminosalicylic acidIBA 04/2022
1	omega-Chloroacetophenone (Mace)IBA 01/2022
1	GLPG0634IBA 01/2022
1	5-(tetradecyloxy)-2-furancarboxylic acid (TOFA)IBA 11/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2020
1	Herpes Zoster VaccineIBA 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 01/2020
1	Creatine Kinase (Creatine Phosphokinase)IBA 11/2019

Therapy/Procedure

35	Therapeutics 04/2022 - 01/2004
4	Biological Therapy 05/2012 - 01/2009
2	Aftercare (After-Treatment) 12/2016 - 11/2015